Humacyte, Inc. (NASDAQ:HUMA) Sees Significant Increase in Short Interest

Humacyte, Inc. (NASDAQ:HUMA) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 19,140,000 shares, a growth of 11.0% from the October 31st total of 17,250,000 shares. Based on an average trading volume of 3,040,000 shares, the short-interest ratio is presently 6.3 days. Currently, 18.5% of the company’s stock are sold short.

Humacyte Stock Down 1.5 %

NASDAQ HUMA traded down $0.07 during trading hours on Monday, hitting $4.45. 2,802,231 shares of the company were exchanged, compared to its average volume of 2,415,096. Humacyte has a 52-week low of $2.45 and a 52-week high of $9.97. The company has a 50 day moving average of $5.22 and a two-hundred day moving average of $6.16. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The firm has a market cap of $560.07 million, a price-to-earnings ratio of -3.37 and a beta of 1.47.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 427,459 shares of the stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now owns 1,992,253 shares in the company, valued at $8,646,378.02. This represents a 17.67 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total transaction of $27,982.80. Following the sale, the director now directly owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. This represents a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,662,886 shares of company stock valued at $7,489,538 over the last 90 days. Corporate insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Endowment Wealth Management Inc. grew its position in shares of Humacyte by 3.1% in the second quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after purchasing an additional 3,000 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Humacyte in the 2nd quarter valued at about $28,000. Private Advisor Group LLC increased its holdings in shares of Humacyte by 1.8% in the 3rd quarter. Private Advisor Group LLC now owns 373,110 shares of the company’s stock valued at $2,030,000 after acquiring an additional 6,510 shares during the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Humacyte by 32.5% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 34,919 shares of the company’s stock worth $168,000 after buying an additional 8,557 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Humacyte by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,955 shares of the company’s stock worth $125,000 after purchasing an additional 8,965 shares during the last quarter. 44.71% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on HUMA shares. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 target price on shares of Humacyte in a research note on Friday, September 20th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of Humacyte in a research note on Wednesday, November 13th. D. Boral Capital reissued a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Thursday, November 21st. Benchmark reissued a “buy” rating and issued a $15.00 target price on shares of Humacyte in a report on Thursday, October 10th. Finally, BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.00.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.